{"id":"placebo-for-tesamorelin","safety":{"commonSideEffects":[]},"_chembl":{"chemblId":"CHEMBL1237026","moleculeType":"Protein"},"_fixedAt":"2026-03-30T12:19:46.372083","_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Placebo is an inert substance used as a control in clinical trials to establish the efficacy of an active drug by comparison. It allows researchers to distinguish between the therapeutic effects of the actual drug and effects due to patient expectation or natural disease progression. In this Phase 3 trial, placebo serves as the comparator arm against tesamorelin, a growth hormone-releasing hormone (GHRH) analog.","oneSentence":"A placebo control contains no active pharmaceutical ingredient and produces no pharmacological effect.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:27:26.289Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Control arm in Phase 3 trial of tesamorelin (active comparator not specified in query)"}]},"_fixedFields":["modality→Peptide"],"trialDetails":[{"nctId":"NCT07481734","phase":"PHASE2","title":"Tesamorelin for Reduction of Liver Fat in Adults With Fatty Liver Disease (Mock Study)","status":"RECRUITING","sponsor":"Hudson Biotech","startDate":"2026-02-02","conditions":"Metabolic Associated Steatotic Liver Disease, Nonalcoholic Steatohepatitis, Hepatic Steatosis","enrollment":120},{"nctId":"NCT06554717","phase":"PHASE2","title":"Tesamorelin as an Adjunct to Exercise for Improving Physical Function in HIV","status":"RECRUITING","sponsor":"Massachusetts General Hospital","startDate":"2025-07-07","conditions":"HIV-1-infection, Frailty, Impaired Physical Function","enrollment":100},{"nctId":"NCT00608023","phase":"PHASE3","title":"TH9507 Extension Study in Patients With HIV-Associated Lipodystrophy","status":"COMPLETED","sponsor":"Theratechnologies","startDate":"2007-08","conditions":"Lipodystrophy, HIV Infections","enrollment":263},{"nctId":"NCT02196831","phase":"NA","title":"Tesamorelin Effects on Liver Fat and Histology in HIV","status":"COMPLETED","sponsor":"Massachusetts General Hospital","startDate":"2015-07-01","conditions":"Human Immunodeficiency Virus (HIV), Nonalcoholic Fatty Liver Disease (NAFLD), Nonalcoholic Steatohepatitis (NASH)","enrollment":61},{"nctId":"NCT02553603","phase":"PHASE1","title":"The Effect of Growth Hormone Releasing Hormone on Cognitive Function in Individuals With Mild Cognitive Impairment","status":"COMPLETED","sponsor":"The University of Texas Medical Branch, Galveston","startDate":"2017-07-18","conditions":"Mild Cognitive Impairment","enrollment":22},{"nctId":"NCT01591902","phase":"PHASE4","title":"Diabetic Retinopathy in HIV Subjects Treated With EGRIFTA®","status":"TERMINATED","sponsor":"Theratechnologies","startDate":"2012-06","conditions":"Diabetic Retinopathy, HIV","enrollment":129},{"nctId":"NCT00675506","phase":"PHASE2","title":"Effectiveness of Growth Hormone Releasing Hormone in Reducing Abdominal Fat in People Who Are Obese","status":"COMPLETED","sponsor":"Massachusetts General Hospital","startDate":"2008-07","conditions":"Abdominal Obesity, Growth Hormone Deficiency","enrollment":60},{"nctId":"NCT01263717","phase":"NA","title":"Effects of Growth Hormone Releasing Hormone in HIV","status":"COMPLETED","sponsor":"Massachusetts General Hospital","startDate":"2010-12","conditions":"HIV, HIV Lipodystrophy","enrollment":54},{"nctId":"NCT01632592","phase":"NA","title":"Abdominal Obesity, Cardiovascular Inflammation, and Effects of Growth Hormone Releasing Hormone Analogue","status":"WITHDRAWN","sponsor":"Massachusetts General Hospital","startDate":"2014-01","conditions":"Abdominal Obesity","enrollment":""},{"nctId":"NCT01264497","phase":"PHASE2","title":"Safety Study of TH9507 in Subjects With Stable, Type 2 Diabetes","status":"COMPLETED","sponsor":"Theratechnologies","startDate":"2002-02","conditions":"Type 2 Diabetes","enrollment":55}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":31,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Placebo for Tesamorelin","genericName":"Placebo for Tesamorelin","companyName":"Theratechnologies","companyId":"theratechnologies","modality":"Small molecule","firstApprovalDate":"","aiSummary":"A placebo control contains no active pharmaceutical ingredient and produces no pharmacological effect. Used for Control arm in Phase 3 trial of tesamorelin (active comparator not specified in query).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":false,"trials":true,"score":3}}